Organon Pharma Indonesia PT (ISX:SCPI) Change In Receivables : Rp0.00 Mil (TTM As of . 20)

View and export this data going back to 1990. Start your Free Trial

What is Organon Pharma Indonesia PT Change In Receivables?

Organon Pharma Indonesia PT's change in receivables for the quarter that ended in . 20 was Rp0.00 Mil. It means Organon Pharma Indonesia PT's Accounts Receivable stayed the same from . 20 to . 20 .

Organon Pharma Indonesia PT's change in receivables for the fiscal year that ended in . 20 was Rp0.00 Mil. It means Organon Pharma Indonesia PT's Accounts Receivable stayed the same from . 20 to . 20 .

Organon Pharma Indonesia PT's Accounts Receivable for the quarter that ended in . 20 was Rp0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Organon Pharma Indonesia PT's liquidation value for the three months ended in . 20 was Rp0.00 Mil.

Organon Pharma Indonesia PT Change In Receivables Historical Data

The historical data trend for Organon Pharma Indonesia PT's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Organon Pharma Indonesia PT Change In Receivables Chart

Organon Pharma Indonesia PT Annual Data

Trend

Change In Receivables

Organon Pharma Indonesia PT Quarterly Data

Change In Receivables

Organon Pharma Indonesia PT Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in . 20 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp0.00 Mil.

Organon Pharma Indonesia PT (ISX:SCPI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Organon Pharma Indonesia PT's Days Sales Outstanding for the quarter that ended in . 20 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=		/		*	91
=

2. In Ben Graham's calculation of liquidation value, Organon Pharma Indonesia PT's accounts receivable are only considered to be worth 75% of book value:

Organon Pharma Indonesia PT's liquidation value for the quarter that ended in . 20 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=		-		+	0.75 *	+	0.5 *
=	0.00

Organon Pharma Indonesia PT Change In Receivables Related Terms

Thank you for viewing the detailed overview of Organon Pharma Indonesia PT's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Organon Pharma Indonesia PT (ISX:SCPI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Organon Pharma Indonesia PT (ISX:SCPI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Jalan Jend Sudirman Kav 21, Sinarmas MSIG Tower, Floor 37 Unit 102 & 106, South Jakarta, IDN, 12920

Website

https://www.organon.com/indonesia

Organon Pharma Indonesia PT engages in the development, manufacture, and distribution of pharmaceutical products. It operates through manufacturing and commercial segments. Manufacturing, which generates the majority of the revenue, is engaged in pharmaceutical manufacturing.

Organon Pharma Indonesia PT (ISX:SCPI) Headlines

No Headlines